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Abstract
Background: Antiretroviral therapy is effective in reducing rates of mother-to child transmission of HIV to low levels in
resource-limited contexts but the applicability and efficacy of these programs in the field are scarcely known. In order to
explore such issues, we performed a descriptive study on retrospective data from hospital records of HIV-infected pregnant
women who accessed in 2007–2010 the Luanda Municipal Hospital service for prevention of mother-to-child transmission
(PMTCT). The main outcome measure was infant survival and HIV transmission. Our aim was to evaluate PMTCT programme
in a local hospital setting in Africa.
Results: Data for 104 pregnancies and 107 infants were analysed. Sixty-eight women (65.4%) had a first visit before or
during pregnancy and received combination antiretroviral treatment (ART) in pregnancy. The remaining 36 women (34.6%)
presented after delivery and received no ART during pregnancy. Across a median cohort follow-up time of 73 weeks,
mortality among women with and without ART in pregnancy was 4.4% and 16.7%, respectively (death hazard ratio: 0.30,
95% CI 0.07–1.20, p=0.089). The estimated rates of HIV transmission or death in the infants over a median follow up time of
74 weeks were 8.5% with maternal ART during pregnancy and 38.9% without maternal ART during pregnancy. Following
adjustment for use of oral zidovudine in the newborn and exposure to maternal milk, no ART in pregnancy remained
associated with a 5-fold higher infant risk of HIV transmission or death (adjusted odds ratio: 5.13, 95% CI: 1.31–20.15,
p=0.019).
Conclusions: Among the women and infants adhering to the PMTCT programme, HIV transmission and mortality were low.
However, many women presented too late for PMTCT, and about 20% of infants did not complete follow up. This suggests
the need of targeted interventions that maintain the access of mothers and infants to prevention and care services for HIV.
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Introduction
Antiretroviral therapy (ART) has proved effective in reducing
rates of mother-to child transmission (MTCT) of Human
Immunodeficiency Virus (HIV) to very low levels not only in
resource-rich countries but also in some resource-limited contexts
[1–5]. Published cohort studies, however, have often considered
only women entering prenatal care at selected sites, who have
good compliance with treatment, and maintain a regular postnatal
care. Clinical trials for the prevention of HIV transmission
(PMTCT) have also shown very good results, but such findings
should be evaluated considering the patient and site selection
process, the frequently scheduled visits, and the adoption of study
procedures that may facilitate therapeutic adherence and
prolonged permanence in care.
It is only partially known to which extent such favourable results
may also be obtained by local PMTCT programs, that several
countries and municipalities have implemented. In such programs,
care is usually provided at a hospital level, and usually depends on
local resources, with no or limited external support from
international agencies or other sources. When implementing a
PMTCT program, local hospitals may adhere to World Health
Organization (WHO) guidelines [6], endorse local guidelines
issued by national authorities, or follow protocols from clinical
trials. However, the applicability of these programs and their
efficacy in the field are scarcely known, and there is limited
information in this context on maternal and infant outcomes and
on the level of program uptake, retention in care, and loss to follow
up. In order to explore such issues, we retrospectively evaluated
the records of a perinatal hospital service in Luanda, Angola, to
evaluate the main outcomes among women and infants accessing a
local program for prevention of HIV mother-to-child transmission.
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Design, setting, and outcomes
The study is a retrospective analysis of mother and infant data
from the hospital records of the perinatal and HIV PMTCT
service of the Municipal Hospital Divina Providencia, a general
population hospital situated in the urban area of Luanda, Angola.
Eligible subjects were HIV-infected pregnant women who
accessed the service between March 2007 and August 2010 and
delivered live newborns. For those women with repeated
pregnancies during the study period, only the last occurred was
considered. Cut-off date for follow up was June 2011. The Ethic
Committee of our institution approved the study design. Written
informed consent was obtained from all the participants in this
study.
Clinical HIV status was defined according to the WHO
definition [6], and CD4 cell counts were measured by flow
cytometry. Gestational age was determined on the basis of the last
menstrual period, ultrasound biometry, or both. Start of treatment
in pregnancy was referred to pregnancy week. Preterm delivery
was defined as delivery before 37 completed weeks of gestation.
Infant feeding was classified as replacement feeding, breastfeeding
or mixed. Replacement feeding and breastfeeding were defined by
exclusive assumption of either replacement feeding or breast milk,
respectively, in the first six months. Mixed replacement/
breastfeeding was defined by alternation of replacement feeding
and breast milk in the first six months or by substitution of
breastfeeding with formula before six completed months of life. In
the newborns, diagnosis (positive tests after 18 months of life) or
exclusion (negative tests before or after 18 months) of HIV
infection required consistent results of two different rapid blood
tests (Determine HIV 1/2, Unipath Limited, Inverness Medical,
Bedford, UK; Uni-Gold HIV, Trinity Biotech, Bray, County
Wicklow, Ireland), in two occasions at least three months apart.
HIV testing for both mothers and infants was free of charge.
The main outcomes evaluated were infant survival, HIV
transmission rate and maternal survival after delivery. The main
variables considered as possible determinants of HIV transmission
were ART during pregnancy, oral zidovudine in the newborn, and
mode of infant feeding.
Program description
Women accessing the HIV PMTCT and perinatal care service
at the Luanda Divina Providencia hospital are managed according
to standardized procedures. Women who become pregnant while
on treatment usually continue the ongoing regimen, unless the
evaluation of treatment suggests a significant risk of toxicity or
teratogenicity. In women with no previous antiretroviral treat-
ment, a CD4 cell count is performed, and antiretroviral treatment
is started soon if CD4 counts are below 350/mm
3 or if the women
has WHO clinical HIV stage III or IV. Otherwise, treatment is
started at the beginning of third trimester. The standard regimen
for pregnant women is zidovudine plus lamivudine plus nevir-
apine, administered twice a day. All antiretroviral drugs are given
free of charge directly to the women in an amount sufficient to
cover the interval between subsequent pregnancy visits (usually
two weeks). Tolerability of treatment is assessed monitoring (free of
charge) haemoglobin (Hb), blood urea nitrogen (BUN), aspartate
aminotransferase (AST) and alanine aminotransferase (ALT),
usually on a monthly basis. Women in clinical HIV stage II or
higher according to the WHO definition also receive cotrimox-
azole, and if tuberculosis (TB) treatment is needed, ART is
suspended and specific TB treatment is given. At delivery, women
receive intravenous zidovudine. If the woman presents before or at
delivery, the newborn receives oral zidovudine within 2 hours
from delivery, continued for the first four weeks of life.
Cotrimoxazole is given to all infants.
Replacement feeding is usually recommended as the preferred
infant mode of feeding, but feeding options are evaluated on a
single case basis, and a 6-month breastfeeding under antiretroviral
treatment may be considered if formula feeding is not regarded as
adequate according to AFASS criteria (acceptable, feasible,
affordable, sustainable and safe). Replacement-feeding mothers
receive free of charge 500 g of powder milk at every infant visit.
After delivery, a CD4 count is performed in all women in order to
evaluate the indication to antiretroviral treatment. Women already
on ART with indication to treatment maintain ART, irrespective
of mode of feeding. In women already on ART but with no
personal indication to treatment, ART is discontinued if exclusive
replacement feeding is the option selected, and otherwise
continued until the end of breastfeeding (usually six months). In
women with no previous ART presenting after delivery, treatment
is started if needed, according to the above treatment recommen-
dations criteria. Follow up of women and their infants takes place
in the same health facility. HIV testing in the infants is performed
at 9, 12 and 18 months, and infants are usually followed at regular
intervals until 24 months of age (usually, with monthly visits).
Statistical analysis
Demographic data were summarized with descriptive statistics.
Quantitative data were compared by either Student’s t-test or
Mann-Whitney U-test, according to the characteristics of data
distribution (normal or skewed, respectively). Categorical data
were compared using the chi-square test or the Fisher test, as
appropriate. Odds ratios (OR) and 95% confidence intervals [CI]
in univariate analyses were calculated by Mantel-Haenszel
estimates.
The variables with a potential association with the main
outcome (HIV transmission or death) in univariate analysis
(p,0.10) were included in a multivariable logistic regression
model which used occurrence of the main outcome as the
dependent variable, calculating an adjusted odds ratio [AOR] with
95% CI for HIV transmission or death. Survival analyses were
based on Kaplan-Meyer analysis, log-rank test, and Cox
regression. Significance levels were set at 0.05. All the analyses
were performed using the SPSS software, version 17.0 (SPSS Inc.,
Chicago, IL, US).
Results
Population
Among 382 women with at least one prenatal or perinatal
service access, 218 (57.1%) were followed for delivery. Among
their infants, 42/218 (19.3%) did not return to the hospital for
follow up evaluations. Following exclusion of 63 infants with
ongoing but limited follow up (with respect to HIV diagnosis), one
transferred infant, three cases with unknown information on
PMTCT, two cases not attending pregnancy visits and three
repeated pregnancies between 2007 and 2010 in the same women,
104 mothers and 107 infants were available for subsequent
analyses (Figure 1). Their general characteristics are shown in
Table 1.
Personal and pregnancy history
Most of the women (96/104, 92.3%) were previously pregnant
at least once (average parity: 2.5). About half of the women (55/
104, 52.9%), however, were not diagnosed with HIV before
current pregnancy, and only 20 (19.2%) had a previous history of
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4. HIV status was unknown for 31 partners (29.8%). Most of the
partners with known HIV status (47/73, 64.4%) were HIV-
infected. First maternal visit occurred before or during pregnancy
for 68 women (65.4%). Among these women, 61 (89.7%)
presented before the end of second trimester (Table 1).
Pregnancy duration and delivery
Data on pregnancy duration was available for 69 women
(66.3%). Preterm delivery involved 22/69 women (31.9%). Most
of the women delivered at the hospital (hospital: 61/104, 58.7%;
home: 11, 10.6%; unknown: 31, 29.8%, other: 1, 1.0%). All the
women with recorded information on mode of delivery (n: 72,
69.2%) delivered vaginally. The main maternal and infant
outcomes are reported in Table 2.
Women who presented before or during pregnancy
For the 68 women with ART during pregnancy (including
women already on treatment at conception), median time of first
visit was week 16 and median week of first antiretroviral treatment
in pregnancy was week 17. The most common antiretroviral
regimen in pregnancy was lamivudine plus zidovudine plus
nevirapine (62/68, 91.2%). All regimens included a backbone of
two nucleosides (zidovudine-lamivudine: 64, stavudine-lamivu-
dine: 3, tenofovir-lamivudine: 1), plus nevirapine (n: 64), efavirenz
(n: 3) or lopinavir/ritonavir (n: 1). Only a few treatment changes
occurred during pregnancy (n: 7, 10.3%), because of drug
intolerance (n:2) and lack of therapeutic response (n: 5, defined
by a CD4 count drop .25%, a viral load increase .30%, or
development of opportunistic infections). Among 62 women with
available information, 40 (64.5%) received intrapartum zidovu-
dine. Among the 71 infants from mothers with ART in pregnancy,
14 (19.7%) received breast milk, through exclusive (11/71, 15.5%)
or nonexclusive (3/71, 4.2%) breastfeeding. Eleven of their
mothers (78.6%) were receiving ART during exclusive or
nonexclusive breastfeeding,
Women who presented post-delivery
Thirty-six women (34.6%) presented after delivery and received
no ART during pregnancy. Most of their infants (31/36, 86.1%)
received maternal milk, through exclusive (25/36, 69.4%) or
nonexclusive (6/36, 16.7%) breastfeeding. In this group only one
infant (2.8%) received oral zidovudine and only one mother (2.8%)
received ART during breastfeeding. Overall, among these mothers
Figure 1. Population flowchart.
doi:10.1371/journal.pone.0036381.g001
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ART because of low CD4 counts or concomitant opportunistic
infections.
Maternal follow up and survival
Cumulative maternal follow up was 159.2 patient-years. Mean
and median maternal follow up after delivery were 82.3 and 73
weeks, respectively. About half of the mothers (n: 51, 49.0%)
received ART in the first six months after delivery. Nine mothers
(8.7%) deceased during follow up (reasons unknown). Mortality
over the follow up was 4.4% (3/68) among women with ART in
pregnancy and 16.7% (6/36) among women with no ART in
pregnancy. Survival probabilities at 96 weeks in a Kaplan-Meier
analysis were 0.95 (95%CI 0.90–1.00) for women with ART in
pregnancy and 0.83 (95%CI 0.70–0.96) for women with no ART
in pregnancy (death hazard ratio: 0.30, 95% CI 0.07–1.20,
p=0.089) (Figure 2). Median values of last CD4 count in women
with and without survival were 491 (n: 95) and 642 (n: 6),
respectively (p=0.179).
Infants’ follow up information
Three of the 104 pregnancies were twin pregnancies, for a total
of 107 infants (male 57, female 50). Cumulative infant follow up
was was 166.0 patient-years. Mean and median infant follow up
were 86.4 and 74.0 weeks, respectively. Infant mode of feeding was
represented by breastfeeding only (n: 36, 33.6%), replacement
feeding only (n: 62, 58.0%) and mixed replacement/formula
feeding (n: 9, 8.4%).
About one quarter of infants with available information (23.8%)
received maternal milk for more than six months. Roughly half of
Table 1. General characteristics.
N Mean Median Interquartile range
Age (years): 104 29.2 29.0 25.0–33.0
Body mass index (kg/m
2): 102 23.1 22.2 20.3–25.5
Number of previous pregnancies: 104 2.9 2.0 1.0–4.0
Number of previous live births: 104 2.5 2.0 1.0–3.7
Week of first visit in pregnancy: 68 16.7 16.0 10.2–22.0
Week of start of ART: 68 14.8 17.0 1.0–22.7
CD4 at first visit in pregnancy (cells/mm
3): 68 372 359 224–486
N%
Primiparous (n: 104): 87 . 7
HIV status of the partner (n: 104): HIV negative 26 25.0
HIV positive 47 45.2
Unknown 31 29.8
HBsAg positive (n: 99): 15 14.4
TB coinfected (n: 104): 98 . 7
WHO HIV disease stage (n: 103): I 50 48.5
II 32 31.1
III 18 17.5
IV 3 2.9
HIV infection diagnosed before current pregnancy (n: 104): 49 47.1
CD4 count ,350 cells/mm
3 at first visit in pregnancy (n: 68): 33 48.5
Antiretroviral treatment before pregnancy (n: 104): 20 19.2
First maternal visit (n:104): before current pregnancy 29 27.9
during current pregnancy 39 37.5
at or after delivery 36 34.6
Trimester of first maternal visit in pregnancy (n: 68
#): first 27 39.7
second 34 50.0
third 7 10.3
Maternal ART in pregnancy
#: overall 68/104 65.4
discontinued after delivery 21/68 30.1
continued during follow up 47/68 69.9
No maternal ART in pregnancy: overall 36/104 34.6
ART started after delivery 17/36 47.2
no ART before or after pregnancy 19/36 52.8
ART: antiretroviral treatment; TB: tuberculosis.
#for women who presented before delivery. Regimens: zidovudine/lamivudine/nevirapine: 62; zidovudine/lamivudine/efavirenz: 2; stavudine/lamivudine/nevirapine: 2;
stavudine/lamivudine/efavirenz: 1; lamivudine/tenofovir/lopinavir: 1;
doi:10.1371/journal.pone.0036381.t001
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of antiretroviral treatment in pregnancy was strongly associated
with subsequent replacement feeding (odds ratio: 25.2, 95% CI
8.3–76.6, p,0.001), ART in the first six months after delivery
(odds ratio: 43.3, 95% CI 9.5–197.6, p,0.001), and oral
zidovudine in the newborn (odds ratio: 130.7, 95% CI 16.5–
1033.2, p,0.001).
Infant survival
Among the infants followed, nine (8.4%) deceased, five (4.7%)
with an unknown HIV status, and four (3.7%) with confirmed
HIV infection. Overall, 97 infants were alive at last follow up,
with ten of them (10.3%) infected. One infant in the group with
no maternal ART was lost to follow up, following an
undetermined HIV test result. In the two groups of infants from
mothers with (n: 71) and without (n: 36) ART during pregnancy,
mortality was 8.5% and 8.3%, respectively. Survival probabilities
at 96 weeks in a Kaplan-Meier analysis were 0.92 (95%CI 0.85–
0.99) for infants from women with ART in pregnancy and 0.94
(95%CI 0.86–1.00) for infants from women with no ART in
pregnancy (death hazard ratio: 2.25, 95%CI 0.42–11.96,
p=0.343) (Figure 3).
HIV transmission
Considering infants with an ascertained HIV status only (n:
101), overall rate of HIV transmission was 13.1% (14/101); HIV
transmission in the two groups of infants from mothers with (n: 66)
and without (n: 35) ART during pregnancy were 1.5% (1/66) and
37.1% (13/35) (odds ratio for HIV transmission: 38.4, 95%CI
4.8–310.7, p=0.001).
HIV transmission or death
Considering infants with known HIV or survival status only (n: 102),
overall, rate of HIV transmission or death was 14.7% (15/102).
Assuming as a worst scenario HIV transmission for all cases with
missing information on HIV status or survival, rate of HIV
transmission or death would be 18.7% (20/107) for the entire group,
8.5% (6/71) among infants from mothers with ART during pregnancy
and 38.9% (14/36) among infants from mothers with no ART during
pregnancy (odds ratio: 6.89, 95%CI 2.36–20.1, p,0.001).
Role of type of feeding and of neonatal zidovudine
prophylaxis
Overall, HIV transmission or death by type of feeding was
36.1% (13/36) with exclusive breastfeeding only, 22.2% (2/9) with
Table 2. Follow up and outcomes.
Overall ART during pregnancy No ART during pregnancy
N Median (IQR) N Median (IQR) N Median (IQR)
Week of change of ART: 7 24.0 (18.0–31.0) 7 24.0 (18.0–31.0) - -
Week of delivery: 69 37.0 (36.0–39.0) 68 37.5 (36.0–39.0) 1 28
Birthweight (g)*: 78 3000 (2600–3400) 62 2900 (2575–3300) 16 3400 (2762.5–3825)
First CD4 count following delivery (cells/mm
3): 101 448 (279–657) 68 493.5 (345–699.5) 33 322 (199–458.5)
Maternal follow up post-delivery (weeks): 104 73.0 (54.0–94.7) 68 61.5 (53–77) 36 109 (78.75–145.75)
Infant follow up (weeks): 107* 74.0 (55.0–99.0) 71 64 (54–79) 36 123.5 (90.25–148.5)
N % N% N%
Preterm delivery: 22/69 31.9 21/68 30.9 1/1 100%
Infant feeding*: Exclusive breastfeeding 36/107 33.6 11/71 15.5 25/36 69.4
Exclusive formula feeding 62/107 58.0 57/71 80.3 5/36 13.9
Mixed 9/107 8.4 3/71 4.2 6/36 16.7
Maternal breastfeeding beyond 6 months: 25/105 23.8 4/71 5.6 21/34 61.8
Maternal ART in the first 6 months after delivery: 51/104 49.0 49/68 72.1 2/36 5.6
Zidovudine to the newborn*: 57/107 53.3 56/71 78.9 1/36 2.8
Cotrimoxazole to the newborn*: 98/107 91.6 69/71 97.2 29/36 80.6
Maternal survival at the end
of follow up:
Overall 95/104 91.3 65/68 95.6 30/36 83.3
ART during and after pregnancy - - 44/47 93.6 - -
ART only after pregnancy - - - - 17/17 100.0
ART only during pregnancy - - 21/21 100.0 - -
No ART before or after pregnancy - - - - 13/19 68.4
Infant status at the end of
follow up*:
HIV-infected, deceased 4/107 3.7 1/71 1.4 3/36 8.3
HIV-unknown, deceased 5/107 4.7 5/71 7.0 - -
HIV-unknown, lost to follow up 1/107 0.9 - - 1/36 2.8
HIV-infected, alive 10/107 9.3 - - 10/36 27.8
HIV-uninfected, alive 87/107 81.3 65/71 91.5 22/36 61.1
IQR: Interquartile range. ART: antiretroviral treatment.
*includes twins.
doi:10.1371/journal.pone.0036381.t002
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Figure 2. Kaplan-Meier Curves for maternal survival with and without ART in pregnancy.
doi:10.1371/journal.pone.0036381.g002
Figure 3. Kaplan-Meier Curves for infant survival with and without maternal ART in pregnancy.
doi:10.1371/journal.pone.0036381.g003
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(7/16), 25.0% (1/4) and 9.5% (2/21) with no postpartum ART
and 30.0% (6/20), 20.0% (1/5) and 7.3% (3/41) in the presence of
postpartum ART. Overall, exposure to maternal milk (mixed or
exclusive breastfeeding) was associated with a significantly higher
risk of HIV transmission or death (unadjusted odds ratio: 5.70,
95%CI 1.89–17.2, p=0.002). Finally, the risk of HIV transmission
or death was significantly higher among infants with no
zidovudine postnatal prophylaxis (16/50, 32.0%), compared to
infants with postnatal zidovudine (4/57, 7.0%; unadjusted odds
ratio: 6.23, 95% CI 1.92–20.23, p=0.002).
Multivariable analysis of HIV transmission and death
In a multivariable analysis that used as covariates ART during
pregnancy, oral zidovudine in the newborn, and exposure to
maternal milk (exclusive or mixed breastfeeding) in the first six
months, no antiretroviral treatment in pregnancy remained
associated with a higher risk of HIV transmission or death
(adjusted odds ratio: 5.13, 95% CI: 1.31–20.15, p=0.019).
Adjusted odds ratios for use of oral zidovudine and exposure to
maternal milk were 2.65 (95%CI 0.51–13.7, p=0.244) and 1.25
(95%CI 0.64–2.46, p=0.509), respectively.
Tolerability of antiretroviral treatment during pregnancy
In women on antiretroviral treatment during pregnancy, the
monitoring of haemoglobin (Hb), blood urea nitrogen (BUN),
aspartate aminotransferase (AST) and alanine aminotransferase
(ALT) showed no significant changes during pregnancy (data not
shown). The occurrence of anaemia in this population was high,
but did not show an increase with the advancing of pregnancy:
overall, the proportion of women with haemoglobin values lower
than 11 g/dl was 82.5% at first trimester and 70.6% at third
trimester. Occurrence of increased levels of AST or ALT was
infrequent: no woman had ALT or AST levels above 5 times the
upper normal limit at any trimester of pregnancy, and only 6
women (9.7%) had during pregnancy a value between two and five
times the upper normal limit.
Discussion
MTCT of HIV is responsible for the vast majority of HIV
paediatric cases, and represents a substantial source of paediatric
mortality in countries with high HIV prevalence [7]. Interventions
have proved effective in reducing rates of HIV transmission, even
in resource-limited settings (RLS) [1–5], and current evidence
from clinical trials and observational studies is periodically
reviewed and translated into recommendations from WHO and
other sources [8–9]. There is currently a widespread effort aimed
at setting up effective local programs against MTCT, and the
impact of some of these programs has been analysed [2,4,10–15].
Our study adds information to this context, describing the
efficacy of a local PMTCT programme at an urban hospital in
Angola. A first finding of our study is that a presentation to care
and initiation of antiretroviral treatment in pregnancy may be
associated with a better maternal survival following delivery:
during a median cohort follow up time of 73 weeks, mortality rates
were 4.4% and 16.7%, respectively, in women with and without
antiretroviral treatment in pregnancy. Although this difference did
not reach statistical significance in a survival analysis, the numbers
were small, and a larger sample might have captured a significant
effect. There is substantial evidence that antiretroviral treatment is
associated with improved survival, and recent data collected in low
income countries even suggest that persons receiving combination
antiretroviral treatment can reach an almost normal life
expectancy [16]. Our data are consistent with a positive effect of
combination treatment in pregnant women that extends beyond
delivery, translating in a better survival, as already reported by
others [14], and indirectly reinforce the concept of using
pregnancy as an important point for HIV testing and for entry
into treatment and care.
In our population, the impact of HIV testing in pregnancy for
entry into care was relevant, because a significant proportion of
the women (52.9%) were unaware of being HIV-infected prior to
accessing the hospital service, and most of them maintained
antiretroviral treatment following delivery. It has also to be
considered that starting antiretroviral treatment in women with a
recent HIV diagnosis is likely to translate, in a context of
serodiscordant couples, into a significantly lower risk of sexual
HIV transmission to the uninfected partners, as recently
demonstrated [17].
Entry of care before delivery was also associated with other
positive interventions against HIV transmission, such as formula
feeding (according to the AFASS criteria) and oral zidovudine
prophylaxis in the newborn: women on antenatal ART had
significantly higher probabilities of a subsequent replacement
feeding (79.4% in this group) and oral zidovudine prophylaxis in
the newborn (78.9%).
The benefits for the infants were straightforward: following
adjustment for oral neonatal zidovudine and exposure to maternal
milk, infants from women with no antiretroviral treatment in
pregnancy had a five-fold increase in the risk of HIV transmission
or death, for a rate of HIV transmission or death of 38.9%
compared to the 8.5% rate observed among infants from women
with ART in pregnancy. Considering infants with an ascertained
HIV status only, we observed a remarkably low rate of HIV
transmission (1.5%), but this rate excludes infants who died before
having their HIV status defined. Cause of death for such infants
was not reported and we could not therefore exclude fatal HIV-
related events in the infants who could not be tested. Because of
this possibility, we preferred to assume HIV transmission for all
the infants deceased (n: 5) or lost to follow up with missing HIV
status information (n: 1).
In terms of infant outcomes, it is expected that between 20%
and 40% of infants born from HIV-infected mothers will
eventually become infected with HIV in the absence of any
intervention.
Local PMTCT programs implemented in resource-limited
settings, despite some differences in the regimens used and in
the context of care, have shown significant reductions in HIV
transmission and mortality, with rates of transmission well below
the above values, particularly when highly active antiretroviral
therapy (HAART) was used [2].
Ekouevi et al. [1] have reported in Cote d’Ivoire a significantly
lower transmission rate among infants with maternal HAART
(2.3%), compared to single dose nevirapine (16.1%), and In two
other PMTCT programs in South Africa and Cameroon, rates of
HIV transmission of 5% [13] and 6.6% [11] were observed. In a
study conducted in 2006–2008 in rural Kenya, occurrence of
MTCT was more frequent (15%), although infant mortality was
relatively limited [15]. The higher transmission rate in this study
might reflect differences in health settings or social conditions, and
might also be a consequence of the earlier diagnosis of infant
infection with virological testing.
Other studies have also reported information on infant
mortality: Kouanda et al. in urban Burkina Faso report a
remarkable null transmission rate with maternal HAART, but
infant mortality was present, even in the subgroup of maternal
HAART [4]. In a PMTCT program conducted in Northern
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among infants was 15.5% [12].
Differences in social conditions and context of care are likely to
greatly influence HIV transmission rate. Even if our local PMTCT
programme may differ from other and often wider programmes
described in the literature, our findings are fully consistent with the
important reductions in HIV transmission obtained by other
HAART-based PMTCT programmes: the HIV-free infant
survival with maternal HAART observed in this study (91.5% at
about 18 months of follow up) is substantially identical to the rate
described within the larger, international-based DREAM pro-
gramme (92.5% at 12 months) [2], and confirms in a different
setting that infants from women attending local hospital PMTCT
programmes may expect a substantially better outcome compared
to the offspring of mothers not accessing PMTCT services. Our
finding of similar survival probabilities in infants from mothers
with and without ART in pregnancy highlight the importance of a
regular follow up infant care, that might be at least as important
(and possibly more important) than maternal ART in pregnancy.
Among the women who received ART in pregnancy, treatment
was well tolerated, with no major complications. Anemia (Hb
,11 g/dl) involved more than two thirds of the women on ART
at third trimester. Similarly high rates have however been
observed in the general population of pregnant women in other
African countries, such as Ghana (54.0%) and southern Benin
(65.7%), suggesting that this condition is quite common even in the
absence of ART, possibly because of concomitant cofactors
[18,19]. In addition, the moderate decrease observed in the rate
of anemia between first and third trimester suggests the safety of
ART in pregnancy, with no significant worsening of hemoglobin
concentrations even in a background of common maternal
anemia. Preterm delivery was relatively common, but the
information on duration of pregnancy was not available for all
the women, and we cannot therefore exclude the possibility of a
selection bias.
Our study has some limitations. First, the findings may be more
easily applicable to urban contexts and less representative of rural
settings, where different conditions may be found. We have also no
information on those women that did not access antenatal care
services and therefore were not reached by the existing
programme. We also were unable to analyze precisely the impact
of time on ART on transmission, because the exact date of start of
ART was not available for all women.
Another important limitation is represented by the frequent loss
to follow up. This limitation is however quite common in PMTCT
programs in restrained-resources settings, and other studies have
clearly shown the need to improve tracking of HIV-exposed
infants [12], prophylaxis uptake, partner testing, and referral for
treatment [10].
In our study, the proportion of women who after a first health
access did not return for delivery or PMTCT was about 40%, and
almost 20% of the infants from HIV-infected mothers did not
return for follow up evaluations. Even if these numbers are
concerning, an even lower coverage has been reported in similar
programmes: Azcoaga-Lorenzo et al. report a 40.4% coverage for
their programme in rural Kenya
15, and in the Ethiopian study by
Mirkuzie et al. only 10.6% of the positive women completed their
follow up to child HIV testing [10].
It is not possible to define to which extent the exclusion of
women lost to follow up and unable to complete the program may
have led to an underestimation of HIV transmission and infant
mortality. Nonetheless, our data on the outcomes of women and
infants who delivered and followed-up in a local PMTCT program
indicate clearly that accessing and following the PMTCT
programmes is associated with significant individual benefits in
terms of HIV transmission and survival. Those data emphasize the
need to recognize and overcome existing barriers to access and
permanence in care in order to improve the program efficacy on a
population basis.
Some studies have addressed this issue: Duff et al. have
identified a major role of economic concerns among women
accessing an antenatal care clinic in Western Uganda: cost of
transportation represented a major barrier to accessing treatment,
together with HIV-related stigma, non-disclosure of HIV status,
long waiting times and suboptimal provider-patient interactions at
the clinic [20]. Lack of support from partners and negative
community reactions were other relevant factors associated with
drop out from a PMTCT program in Malawi [21].
In resource limited settings, the prevention of HIV vertical
transmission seems to be adequately effective only if accompanied
by an integrated approach that takes into account patients’ social
conditions and local difficulties. Integrating PMTCT with other
services may improve linking to care and reduce the attrition rate,
as suggested by the limited loss to follow up reported by
programmes with a comprehensive treatment of HIV, malnutri-
tion, and other concomitant diseases [2]. Involving communities is
also an important component, and might facilitate tracking of
infants, treatment uptake, and individual support. Education has
also a key role, because higher levels of knowledge about HIV and
PMTCT are associated with referral for testing [22], and might
promote early diagnosis, and initiation of HAART before onset of
symptomatic disease [20]. Assessment of gender issues, economical
empowerment of the women, minimization of stigma and support
from the community are also important [21]. In general, social
conditions influence dramatically the outcome of preventive efforts
against HIV transmission. Therefore, individually effective
biomedical interventions, including antiretroviral therapy for
PMTCT, will not be effective at a population level without
concomitant interventions on the social environment that include
education, women empowerment, minimization of stigma,
accessibility of care and community involvement.
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